ABT240927C112000
- 1.14
- -1.10-49.11%
Abbott Laboratories Newsroom
Abbott Hosts Conference Call for Third-Quarter Earnings
Institutional Owners May Ignore Abbott Laboratories' (NYSE:ABT) Recent US$8.3b Market Cap Decline as Longer-term Profits Stay in the Green
Piper Sandler initially assigned an "shareholding" rating to abbott laboratories.
On September 20th, Piper Sandler covered Abbott Laboratories for the first time, giving it an 'overweight' rating with a target price of $131.
Abbott Laboratories To Go Ex-Dividend On October 15th, 2024 With 0.55 USD Dividend Per Share
September 19th (Eastern Time) - $Abbott Laboratories(ABT.US)$ is trading ex-dividend on October 15th, 2024.Shareholders of record on October 15th, 2024 will receive 0.55 USD dividend per share on
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Express News | Abbott Declares 403Rd Consecutive Quarterly Dividend
Express News | Abbott - Declared a Quarterly Common Dividend of 55 Cents per Share.
Press Release: Abbott Declares 403rd Consecutive Quarterly Dividend
Abbott a New Overweight at Piper Sandler; at Attractive Entry Point
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Abbott Laboratories' (NYSE:ABT) Stock Been Rising: Are Strong Financials Guiding The Market?
Abbott Laboratories Analyst Ratings
Piper Sandler Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $131
Piper Sandler analyst Adam Maeder initiates coverage on $Abbott Laboratories(ABT.US)$ with a buy rating, and sets the target price at $131.According to TipRanks data, the analyst has a success rate
Buy Rating on Abbott Laboratories: Undervalued With Strong Growth Prospects Despite NEC Litigation
Express News | Abbott : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $131
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
Express News | Sichuan Kelun Pharmaceutical: Diquinon Tablets Obtains Pharmaceutical Registration Approval.
Senseonics Eversense 365 Glucose Monitor Cleared in the U.S.
New Survey From Abbott Finds Epidemiologists Believe Viral and Mosquito-Borne Pathogens Are Priority Concerns for Disease Outbreaks
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month